Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

109.39 +4.16 (+3.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings
 
Via Benzinga
Where Axsome Therapeutics Stands With Analysts
 
Via Benzinga
Axsome Therapeutics Inc (NASDAQ:AXSM) Reports Q2 2025 Revenue Beat and Narrower EPS Loss, Shares Surge 6% in Pre-Market Trading
Axsome Therapeutics beats Q2 2025 revenue estimates with $150M, driven by Auvelity's 84% YoY growth. Shares rise 6% pre-market on improved EPS. 
Via Chartmill
Axsome (AXSM) Q2 Revenue Soars 72%
Via The Motley Fool
Topics Intellectual Property
Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For August 4, 2025
 
Via Benzinga
A Look at Axsome Therapeutics's Upcoming Earnings Report
 
Via Benzinga
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Via The Motley Fool
Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Where Axsome Therapeutics Stands With Analysts
 
Via Benzinga
Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS)
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
From Axsome Therapeutics, Inc.
Via GlobeNewswire
FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required
The FDA rejected Axsome's AXS-14 fibromyalgia, prompting a new trial and pushing the expected drug launch to 2028. 
Via Benzinga
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews
 
Via Benzinga
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability
The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review. 
Via Stocktwits
Topics Stocks
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Soaring Stocks Wth More Upside Potential
Via The Motley Fool
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts
 
Via Benzinga
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.